The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000435381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
17/11/2025
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
7/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Clinical Trial to Determine Safety and Tolerability of Targeted Osmotic Lysis in the Treatment of participants with Well-Differentiated Cutaneous Squamous Cell Carcinoma
Scientific title
A Clinical Trial to Determine Safety and Tolerability of Targeted Osmotic Lysis in the Treatment of Well-Differentiated Cutaneous Squamous Cell Carcinoma.
Additional trial identifiers [1] 315625 0
VCC-TOL-01
Universal Trial Number (UTN)
Trial acronym
TOL in CSCC
Related trial records

Health condition
Health condition(s) studied:
Cutaneous Squamous Cell Carcinoma 339801 0
Condition category
Condition code
Skin 336039 336039 0 0
Dermatological conditions
Cancer 336040 336040 0 0
Non melanoma skin cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The new treatment is the Targeted Osmotic Lysis system (TOL) which combines a common heart medication (called Digoxin) with electrical pulses (PEF Stimulation) from a new Coaxial Pulsed Electrical Field Generator (CPEFG) at the same time. The CPEFG is a new device that pulses a low voltage electric field and targets cancer cells. This study is testing the TOL system which includes digoxin. Digoxin is an older, well-established medication used in Australia for certain cardiac conditions, but it is not approved for the treatment of CSCC. Participants will be required to take an oral tablet dose of between 0.125 – 0.5mg daily. Digoxin dosing will be individualised based on the participant's age, weight, and renal function. The CPEFG, in conjunction with Digoxin forms the TOL system. The CPEFG device uses a set of circular rings placed around the body to create a gentle, low-voltage electrical field while the participant lies comfortably on a table. The electrical field (using a low voltage of 18 volts) is carefully controlled to be even and consistent in the area being treated. The intervention will be administered by a dermatologist.

The study consists of 3 phases:

1. Pre-treatment Period: (up to 14 days before the TOL treatment starts)
2. Active treatment Period: (6 in person visits and 3 phone calls, over a period of 3 weeks)
3. Post-Treatment Follow-Up Period (5 in person visits, for up to 12 months)

During the active treatment period, participants will have three (3) cycles of treatment, each treatment cycle consisting of two (2) hours on two (2) consecutive days, over three (3) weeks There will be six (6) days between cycles. For example, from completion of day two (2) in cycle one (1), there are six (6) days until commencement of day one (1) in cycle 2. During each Treatment Day, vital signs, ECGs, and treatment photographs will be performed, along with two (2) hours of electrical pulses from the CPFEG device. Each treatment day visit will take approximately 3 hours.
Intervention code [1] 332586 0
Treatment: Devices
Intervention code [2] 332816 0
Treatment: Drugs
Description of the comparator or control
No Control Group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 343583 0
Safety
Timepoint [1] 343583 0
12 months after final TOL session
Primary outcome [2] 343584 0
Efficacy
Timepoint [2] 343584 0
6 weeks after final TOL treatment
Secondary outcome [1] 456180 0
Patient reported change in quality of life over the study period
Timepoint [1] 456180 0
At Baseline, and each follow-up visit (3 days, 3-weeks, 8 weeks, 6 months & 12 months Post Treatment)
Secondary outcome [2] 456185 0
Patient Perspectives
Timepoint [2] 456185 0
At End of Study Visit (12 months Post Treatment)

Eligibility
Key inclusion criteria
1. Age range 40-75 years old
2. Confirmed diagnosis of well-differentiated cutaneous squamous cell carcinoma (CSCC) on the chest, back, legs, arms and abdomen, with lesion(s) <2cm in diameter.
3. Confirmed VGSC overexpression of the target lesion.
4. Participants must be sufficiently mobile to be able to move themselves in and out of the CPEFG with minimal assistance.
5. The participant is willing and able to provide informed consent
6. The participant must be willing and able to comply with the requirements of the protocol and follow directions from the clinic staff.
Minimum age
40 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Acute intercurrent illness or unstable clinical condition as determined by the treating physician or medical monitor.
2. Major surgery requiring general anesthesia within 12 weeks.
3. Second malignancy other than non-melanoma skin cancer within the preceding 5 years.
4. Weight greater than or equal to 136 kg.
5. Participants with recurrent cutaneous squamous cell carcinoma
6. Participants with metal implants
7. Participants with documented heart failure
8. Clinically significant hepatic, renal, or cardiac dysfunction, including:
a. Total bilirubin >1.5mg/dL or AST/ALT >2.5 x ULN
b. Creatinine clearance (CrCl < 30ml/ min
c. LVEF 3.0 or hemopoietic suppression, hemoglobin < 8 g/dl.
9. Clinically significant abnormality of coagulation, international normalized ratio (INR) level >3.0 or hemopoietic suppression, hemoglobin < 8 g/dl.
10. Abnormal ECG including:
a. bradycardia 450msec
c. AV block grade II or higher
d. Interventricular conduction delay with a QRS over 120 msec.
11. Cardiovascular conditions that contraindicate use of cardiac glycosides (e.g. atrial fibrillation, ventricular tachycardia, ventricular fibrillation, IHSS, sick sinus syndrome, AV block, restrictive cardiomyopathy, cor pulmonale, constrictive pericarditis, hypokalemia, renal impairment, and thyroid disease).
12. Central nervous system tumour or metastasis.
13. Participants who are immunosuppressed or immunodeficient
14. Pregnant or lactating.
15. Participants of childbearing potential who are unwilling or unable to use highly effective contraception (e.g. intra-uterine device, bilateral tubal ligation, vasectomized partner).
16. Participated in another clinical investigation within 3 months.
17. Participants that are on sodium channel blocking agents, (e.g., tricyclic anti-depressants, anti-epileptic agents, Class I anti-arrhythmic, or the anti-anginal agent ranolazine within 4 weeks of the first TOL treatment.
18. Current use of drugs with significant drug-drug interaction with digoxin or allopurinol.
19. Intolerance of, contra-indicated or allergic to digoxin or allopurinol.
20. Those who, in the judgement of the treating physician, investigator, or study monitor have any clinically significant ongoing medical condition (excluding the participant’s cancer), e.g., discovery of a previously unidentified adverse reaction to the cardiac glycoside, that might jeopardize the participant’s safety or interfere with the absorption, distribution, metabolism or excretion of the digoxin.


Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 28813 0
Novatrials - Kotara
Recruitment postcode(s) [1] 45050 0
2289 - Kotara

Funding & Sponsors
Funding source category [1] 320226 0
Commercial sector/Industry
Name [1] 320226 0
Oleander Medical Australia Pty. Ltd.
Country [1] 320226 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Oleander Medical Australia Pty. Ltd.
Address
Country
Australia
Secondary sponsor category [1] 322792 0
None
Name [1] 322792 0
Address [1] 322792 0
Country [1] 322792 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318767 0
Bellberry Human Research Ethics Committee H
Ethics committee address [1] 318767 0
Ethics committee country [1] 318767 0
Australia
Date submitted for ethics approval [1] 318767 0
22/10/2025
Approval date [1] 318767 0
04/03/2026
Ethics approval number [1] 318767 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 145202 0
Dr Juliana Junger
Address 145202 0
Novatrials, Suite 301/99 Pacific Hwy, Charlestown NSW 2290
Country 145202 0
Australia
Phone 145202 0
+61 02 4089 3744
Fax 145202 0
Email 145202 0
Contact person for public queries
Name 145203 0
Stephanie Rufo
Address 145203 0
Stephanie Rufo Clinical Consulting, PO Box 14, Mayfield NSW 2304
Country 145203 0
Australia
Phone 145203 0
+61 423 666 467
Fax 145203 0
Email 145203 0
Contact person for scientific queries
Name 145204 0
Stephanie Rufo
Address 145204 0
Stephanie Rufo Clinical Consulting, PO Box 14, Mayfield NSW 2304
Country 145204 0
Australia
Phone 145204 0
+61 423 666 467
Fax 145204 0
Email 145204 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.